Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177281 · ClinicalTrials.gov registry record · Phase 1
Safety Study of S-CKD602 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00177281 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 45 participants.
The verdict
NCT00177281, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate a new anti-cancer drug called S CKD602, developed by ALZA Corporation. The drug is investigational and not approved by the Food and Drug administration (FDA). The side effects (the way the drug acts in your body) and the effect it has on your disease will be studied.
Interventions
- DRUG S CKD602
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177281
The ClinicalTrials.gov registry entry for NCT00177281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which S CKD602 is the first listed.
NCT00177281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177281 about?
NCT00177281 is a clinical study titled "Safety Study of S-CKD602 in Patients With Advanced Malignancies". The purpose of this research study is to evaluate a new anti-cancer drug called S CKD602, developed by ALZA Corporation. The drug is investigational and not approved by the Food and Drug administration (FDA). The side effects (the way the drug acts in your body) and the effect it has on your disease...
What is the current status of trial NCT00177281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2003-09. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00177281?
The interventions under investigation include: S CKD602 (DRUG).
Who is sponsoring clinical trial NCT00177281?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.